An evaluation of avelumab for the treatment of genitourinary tumors

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Surveillance E, And end results program. Cancer Stat Facts: kidney and renal pelvis cancer; [cited 2019 Mar 04]. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review 1975-2013. National Cancer Institute. 2016. Available from: https://www.seer.cancer.gov/archive/csr/1975_2016/#contents.
   Google Scholar
• Bedke J, Gauler T, Grünwald V, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35(2):179–188.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Bedke J, Stühler V, Stenzl A, et al. Immunotherapy for kidney cancer: status quo and the future. Curr Opin Urol. 2018;28(1):8–14.
   PubMed Web of Science ®Google Scholar
• Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol. 2018;59(5):285–296.
   PubMed Web of Science ®Google Scholar
• Stühler V, Maas JM, Bochem JEA. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. World J Urol. 2019;37(9):1773–1784.
   PubMed Web of Science ®Google Scholar
• Medina PJ, Adams VR. PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses. Pharmacother J Human Pharmacol Drug Ther. 2016;36(3):317–334.
   Google Scholar
• Stühler V, Maas JM, Rausch S, et al. Immune checkpoint inhibition for the treatment of renal cell carcinoma. Expert Opin Biol Ther. 2020;20(1):83–94.
   PubMed Web of Science ®Google Scholar
• Li X, Shao C, Shi Y, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11(1):31.
   PubMedGoogle Scholar
• Brown JA, Dorfman DM, Ma F-R, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170(3):1257–1266.
   PubMed Web of Science ®Google Scholar
• Heery CR, O’Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–598.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–1385.
   PubMed Web of Science ®Google Scholar
• Rao A, Patel MR. A review of avelumab in locally advanced and metastatic bladder cancer. Ther Adv Urol. 2019;11:1756287218823485.
   Web of Science ®Google Scholar
• Heery CR, Coyne GHOS, Madan RA, et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J clin oncol. 2014;32(15_suppl):3064.
   Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122.
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti–PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–1157.
   PubMed Web of Science ®Google Scholar
• Donahue RN, Lepone LM, Grenga I, et al. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J Immunother Cancer. 2017;5(1):20.
   PubMedGoogle Scholar
• Fujii R, Friedman ER, Richards J, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016;7:23.
   PubMedGoogle Scholar
• Grenga I, Donahue RN, Lepone LM, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016;(5):e83. DOI:10.1038/cti.2016.27
   PubMedGoogle Scholar
• Jochems C, Hodge JW, Fantini M, et al. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. Int J Cancer. 2017;141(3):583–593.
   PubMed Web of Science ®Google Scholar
• Khanna S, Thomas A, Abate-Daga D, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti–PD-L1 antibody avelumab. J Thorac Oncol. 2016;11(11):1993–2005.
   PubMed Web of Science ®Google Scholar
• Crescioli S, Correa I, Karagiannis P, et al. IgG4 characteristics and functions in cancer immunity. Curr Allergy Asthma Rep. 2016;16(1):7.
   PubMed Web of Science ®Google Scholar
• Ibrahim R, Stewart R, Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. 2015;42(3):474–483.
   PubMed Web of Science ®Google Scholar
• Wilkins JJ, Brockhaus B, Dai H, et al. Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in merkel cell carcinoma and urothelial carcinoma. CPT Pharmacometrics Syst Pharmacol. 2019;8(6):415–427.
   PubMedGoogle Scholar
• Novakovic AM, Wilkins JJ, Dai H, et al. Changing body weight–based dosing to a flat dose for avelumab in metastatic merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther.
   Web of Science ®Google Scholar
• Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J clin oncol. 2017;35(19):2117–2124.
   PubMed Web of Science ®Google Scholar
• Tan S, Zhang CW, Gao GF. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduct Target Ther. 2016;1:16029. DOI:10.1038/sigtrans.2016.29
   PubMed Web of Science ®Google Scholar
• Vaishampayan U, Schöffski P, Ravaud A, et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019;7(1):275.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Motz GT, Busch J, et al. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. In: Dranoff Geditor. Cancer Immunology and Immunotherapy. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 129–148.
   Google Scholar
• Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J clin oncol. 2014;32(15_suppl):5010.
   Google Scholar
• Choueiri TK, Larkin JMG, Pal SK. Efficacy and biomarker analysis of patients with advanced renal cell carcinoma with sarcomatoid histology: subgroup analysis from the phase III JAVELIN renal 101 trial. Ann Oncol. 2019;30(suppl_5):v356–v402.
   Google Scholar
• O’Donnell PH, Balar AV, Vuky J, et al. KEYNOTE-052: phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— updated response and survival results. J clin oncol. 2019;37(15_suppl):4546.
   Web of Science ®Google Scholar
• Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–2415.
   PubMed Web of Science ®Google Scholar
• Balar AV, Dreicer R, Loriot Y, et al. Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): long-term efficacy from phase 2 study IMvigor210. J clin oncol. 2018;36(15_suppl):4523.
   Web of Science ®Google Scholar
• Siefker-Radtke AO, Baron AD, Necchi A, et al. Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: efficacy and safety update from CheckMate 275. J clin oncol. 2019;37(15_suppl):4524.
   Web of Science ®Google Scholar
• Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3(9): e172411-e172411. doi:10.1001/jamaoncol.2017.2411.
   PubMed Web of Science ®Google Scholar
• Bex A, Thienen JVV, Schrier M, et al. A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). Future Oncol. 2019;15(19):2203–2209.
   PubMed Web of Science ®Google Scholar
• Bukhari N, Al-Shamsi HO, Azam F. Update on the treatment of metastatic urothelial carcinoma. ScientificWorldJournal. 2018;2018:5682078.
   PubMedGoogle Scholar
• BioSpace. BAVENCIO significantly improved overall survival in patients with locally advanced or metastatic urothelial carcinoma [news release]. 2020 Jan 6 [cited 2020 Jan 6]. Available from: prnewswire.com/news-releases/bavencio-significantly-improved-overall-survival-in-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-300981078.html.
   Google Scholar
• Chanza NM, Roumeguere TA, Sideris S, et al. Avelumab as neoadjuvant therapy in subjects with muscle-invasive urothelial carcinoma (AURA trial). J clin oncol. 2018;36(6_suppl):TPS535–TPS535.
   Google Scholar
• Fakhrejahani F, Madan RA, Dahut WL, et al. Avelumab in metastatic castration-resistant prostate cancer (mCRPC). J clin oncol. 2017;35(6_suppl):159.
   Google Scholar
• Vida AR, Taus A, Pons B, et al. Phase Ib study of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer progressing after one line of chemotherapy and one novel androgen receptor axis inhibitor. J clin oncol. 2018;36(15_suppl):TPS5089–TPS5089.
   Web of Science ®Google Scholar
• ClinicalTrials.gov, D.d.U.S.N.L.o.M.
   Google Scholar
• Kelly K, Infante JR, Taylor MH, et al. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018;124(9):2010–2017.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856.
   PubMed Web of Science ®Google Scholar
• Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023–5039.
   PubMed Web of Science ®Google Scholar
• Powles T, Smith K, Stenzl A, et al. Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol. 2017;72(4):477–481.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Aubry MC, Moser JC, et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016;27(10):1953–1958.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Murphy SJ, Peikert T, et al. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res. 2016;22(9):2177–2182.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Albiges L, Haanen JBAG, et al. Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J clin oncol. 2019;37(15_suppl):101.
   Web of Science ®Google Scholar
• Necchi A, Raggi D, Sonpavde G, et al. Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): comparing outcomes of immunotherapy (IT) versus single agent and doublet chemotherapy (CT). J clin oncol. 2017;35(6_suppl):341.
   Web of Science ®Google Scholar
• Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site — when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409–1412.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2020;21(1):105–120.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• Strauss J, Heery CR, Schlom J, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287–1295.
   PubMed Web of Science ®Google Scholar
• Zhang F, Qi X, Wang X, et al. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget. 2017 Oct 6;8(52):90215–90224. doi:10.18632/oncotarget.21652
   PubMedGoogle Scholar
• Tan S, Liu K, Chai Y, et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9(1):135–139. doi:10.1007/s13238-017-0412-8
   PubMed Web of Science ®Google Scholar
• Tan S, Zhang H, Chai Y, et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017 Feb 6;8:14369. doi:10.1038/ncomms14369
   PubMed Web of Science ®Google Scholar
• He M, Chai Y, Qi J, et al. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget. 2017 May 19;8(40):67129–67139. doi:10.18632/oncotarget.18004
   PubMedGoogle Scholar